Sentences with phrase «lung cancer testing»

Not exact matches

Darzalex, however, has not yet reached its peak potential as the drug moves into earlier stages of the disease and is being tested on solid tumours like lung cancer.

The company has performed thousands of tests and is working on detecting prostate, breast, colon, and lung cancers.

Less than a year after growth picked up at the test prep company, Hansoo Lee, Parikh's co-founder, passed away from lung cancer.

Now a new clinical trial is under way, by New York's Mount Sinai, to test a vaccine to combat recurrence in some of the most deadly forms of cancer, including lung, breast, gynecological and bladder cancers.

Mount Sinai is testing a «personalized» vaccine, aimed at combating recurrence in some of the most deadly forms of cancer, including lung, breast, gynecological and bladder cancers.

The medicines, which help unleash the immune system on cancer cells, were tested in patients with advanced lung cancer.

Freenome says its tests do better than the current options for diagnosing prostate, breast, colorectal, and lung cancers.

Mount Sinai in NY is among the first to test a personalized vaccine for lung, breast, gynecological and bladder cancers.

With lung cancer, for example, it wants to be able to resolve whether a test shows non-small-cell lung carcinoma or small cell lung carcinoma.

Indeed, the 25 - person company has now tested thousands of blood samples, and it says its tests outperform current screening tests on the market for four types of cancer: prostate, breast, colorectal, and lung.

The study has been tested in metastatic patients with different primary tumours such as breast, colon and lung cancer.

A team led by Lu You, an oncologist at Sichuan University's West China Hospital in Chengdu, plans to start testing such cells in people with lung cancer next month.

In their latest study, they tested compounds against cells from nine different types of human cancer, including common types affecting blood, colon, breast, prostate, ovaries, kidneys, and lungs.

Among other tests, they looked at tissue samples of breast cancer that had spread to the liver, lung and other organs.

Since the Lung Cancer Mutation Consortium trial began in 2009, many patients are now tested for mutated or altered genes before treatment.

«In addition to lung cancer, we've also tested for ovarian cancer in this work.

The clinical trial being planned will test the treatment in both lung cancer patients and those with glioblastomas.

We extended our molecular diagnostics to test for a genetic rearrangement that had been reported in lymphoma and lung cancer, but never in mesothelioma.

HDAC inhibitors have been approved for use in blood cancers and are being tested for benefit in other cancers, such as breast, colorectal, gastric, liver, lung and prostate cancers that overexpress specific HDAC proteins.

The company also tested the virus in a 23 - person, early - stage trial against colorectal, lung, ovarian and skin cancers.

Finally, a Calgary, Alberta — based company, Oncolytics Biotech, is testing a reovirus (an RNA virus often found in human lungs but thought to be nonpathogenic) against several types of cancer, including that of the lung and skin as well as head and neck malignancies.

The five types of cancers analyzed in this study have screening methods that allow for detection at an early stage, though in some instances, debate remains over efficacy and appropriate use: mammography for breast cancer, colonoscopy for colorectal cancer, Pap smear and / or HPV test for cervical cancer, spiral computed tomography or CT for lung cancer, and PSA test for prostate cancer.

She expects she will find laminum - 8 uniquely overexpressed in other invasive cancers, like lung and colon cancer, but to date she has tested for it in only human brain and metastatic breast cancer.

Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.

In the first series of tests, researchers found that luteolin inhibited the metastasis of triple - negative cancer in the lungs of affected mice.

To test the notion, the scientists examined DNA from four lung cancer patients, isolating fragments that were 20 - 50 base pairs shorter than the total average size in circulation.

To test this idea, the researchers utilized two mouse models of human breast cancer metastasis and found dormant disseminated tumor cells residing upon the membrane microvasculature of lung, bone marrow and brain tissue.

«This study demonstrates the value of testing lung cancer tissue for an ALK rearrangement, and it underscores the potential of cancer genomics to target cancer treatments to each patient,» says the study's senior author, Pasi A. Jänne, MD, PhD, who is the director of the Lowe Center for Thoracic Oncology of Dana - Farber.

The researchers are planning to test this method to deliver HIV vaccines in nonhuman primates, and they are also working on further developing cancer vaccines, including one for lung cancer.

Right now, the tests, which are available from several companies, mostly aid in treatment decisions for people already diagnosed with a particular form of cancer, such as prostate or lung.

The research, presented at the European Respiratory Society (ERS) International Congress in Munich, suggests that testing the temperature of breath could be a simple and noninvasive method to either confirm or reject the presence of lung cancer.

The researchers enrolled 82 people in the study who had been referred for a full diagnostic test after an x-ray suggested the presence of lung cancer.

In a test designed to show how the tool would be used in actual practice, Dr. Wang retrospectively tested iCAGES using detailed sequencing data from a patient with lung cancer.

They also tested other cancer lines — human cervical, lung and prostate cancers — and found that they responded to the patterned tumor environments in the same way.

If we are able to refine a test to diagnose lung cancer by measuring breath temperature, we will improve the diagnostic process by providing patients with a stress - free and simple test that is also cheaper and less intensive for clinicians.»

«Breath temperature test could identify lung cancer.»

One early project was to help Genoptix — a Novartis daughter - company acquired in 2011 and located in Carlsbad, California — to commercialize a diagnostic test for lung cancer patients.

Testing for the EGFR mutation and ALK rearrangements and the use of targeted therapies have given lung cancer patients the chance for survival, along with improved quality of life and time with loved ones.

Tested on data from The Cancer Genome Atlas (TCGA), MEGENA identified novel regulatory targets in breast and lung cancers, outperforming other co-expression analysis methods.

In an era of precision medicine, the guideline provides recommendations for pathologists, oncologists, and other cancer health professionals on the current state - of - the - art recommendations for the molecular testing of lung cancer.

«Rapid advancements in genetic testing offer new treatment options for patients with advanced lung cancer.

Moving forward, they plan to continue testing derivatives of HIPP for the treatment of colon cancer and also see if their findings extend to breast, lung, ovarian and prostate cancers.

In tests on EGFR - dependent lung cancer cell lines, Tan and colleagues show that the drugs gefitinib and bosutinib «showed additive and synergistic effects.»

«For about 80 percent of our patients with lung cancer, we don't have tests like [the one for] ALK to tell us what treatments will work best,» Shaw says.

The researchers are now doing clinical testing on breast, lung, stomach, prostate and intestinal cancer patients» blood samples.

The group is applying advanced image analysis techniques to 4D CT scans already performed as a standard step in targeting lung cancer radiotherapy, to map areas of lung function without additional testing.

«In my case, this was even more rare since I have a different version of lung cancer than most people who were being tested on Xalkori,» he adds.

The difference with Xalkori is that a test exists to identify that slim percentage of lung cancer patients (about 8,000 people in the United States and 40,000 worldwide each year) who would respond well.

Scientists from the Cancer Research UK Manchester Institute, based at The University of Manchester and part of the Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug — known as AZD3965 — on small cell lung cancer Cancer Research UK Manchester Institute, based at The University of Manchester and part of the Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug — known as AZD3965 — on small cell lung cancer Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug — known as AZD3965 — on small cell lung cancer cancer cells.

The Manchester researchers tested a new drug that targets one of these molecules, MCT1, in lung cancer cells and in mouse models.